Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Summary

Phase 1–2 study of daraxonrasib (RMC-6236), an oral RAS(ON) multiselective inhibitor targeting GTP-bound mutant and wild-type RAS, in 168 patients with previously treated RAS-mutated PDAC. Among 26 patients with RAS G12 mutations receiving 300 mg in second line: ORR 35%, median duration of response 8.2 months, mPFS 8.5 months, mOS 13.1 months. Grade ≥3 treatment-related adverse events in 30%.